Martin R. Sprick

List of Publications by Year
in descending order

59 papers	7,980 citations	94433 37 h-index	155660 55 g-index
62 all docs	62 docs citations	62 times ranked	12575 citing authors

#	Article	IF	Citations
1	Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 2010, 12, 468-476.	10.3	1,623
2	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 2013, 31, 539-544.	17.5	920
3	FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2. Immunity, 2000, 12, 599-609.	14.3	748
4	Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13427-13432.	7.1	654
5	The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation. Cancer Research, 2010, 70, 719-729.	0.9	326
6	Cancer stem cells â€“ old concepts, new insights. Cell Death and Differentiation, 2008, 15, 947-958.	11.2	320
7	Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO Journal, 2002, 21, 4520-4530.	7.8	303
8	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 2016, 22, 278-287.	30.7	184
9	Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death and Differentiation, 2004, 11, S86-S96.	11.2	178
10	The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 125-132.	4.1	178
11	Screening drug effects in patientâ€derived cancer cells links organoid responses to genome alterations. Molecular Systems Biology, 2017, 13, 955.	7.2	163
12	Survival of pancreatic cancer cells lacking KRAS function. Nature Communications, 2017, 8, 1090.	12.8	131
13	Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. Gastroenterology, 2010, 138, 2357-2367.	1.3	130
14	Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1147-E1156.	7.1	128
15	Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligandâ€“Induced Apoptosis. Clinical Cancer Research, 2007, 13, 3403-3412.	7.0	115
16	Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation. Molecular and Cellular Biology, 2003, 23, 777-790.	2.3	109
17	TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 2007, 45, 649-658.	7.3	108
18	A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell, 2015, 162, 146-159.	28.9	100

#	Article	IF	Citations
19	TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus. Journal of Immunology, 2003, 170, 1814-1821.	0.8	97
20	The linear ubiquitin chain assembly complex regulates <scp>TRAIL</scp>â€induced gene activation and cellÂdeath. EMBO Journal, 2017, 36, 1147-1166.	7.8	90
21	Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene, 2008, 27, 3211-3220.	5.9	89
22	Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-ÎºB Activation and Cell Survival. Cell Reports, 2017, 19, 785-797.	6.4	84
23	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research, 2018, 24, 351-359.	7.0	81
24	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1240859.	4.6	75
25	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer, 2015, 15, 403.	2.6	70
26	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer, 2014, 14, 512.	2.6	65
27	Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin. Cancer Discovery, 2021, 11, 638-659.	9.4	65
28	Biochemistry and function of the DISC. Trends in Biochemical Sciences, 2001, 26, 452-453.	7.5	64
29	NF-ÎºB Inhibition Reveals Differential Mechanisms of TNF Versus TRAIL-Induced Apoptosis Upstream or at the Level of Caspase-8 Activation Independent of cIAP2. Journal of Investigative Dermatology, 2008, 128, 1134-1147.	0.7	61
30	TRAIL-Induced Apoptosis and Gene Induction in HaCaT Keratinocytes: Differential Contribution of TRAIL Receptors 1 and 2. Journal of Investigative Dermatology, 2003, 121, 149-155.	0.7	59
31	Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene, 2013, 32, 1539-1548.	5.9	55
32	The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features. Breast Cancer Research, 2015, 17, 146.	5.0	54
33	Tumor microvasculature supports proliferation and expansion of gliomaâ€propagating cells. International Journal of Cancer, 2009, 125, 1222-1230.	5.1	53
34	cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-ÎºB Activation at the Death-inducing Signaling Complex in Human Keratinocytes. Journal of Biological Chemistry, 2004, 279, 52824-52834.	3.4	46
35	CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death and Differentiation, 2015, 22, 1192-1202.	11.2	45
36	Single cell polarity in liquid phase facilitates tumour metastasis. Nature Communications, 2018, 9, 887.	12.8	45

#	Article	IF	Citations
37	Potential Role of Soluble TRAIL in Epithelial Injury in Children with Severe RSV Infection. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 697-705.	2.9	38
38	Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 678-686.	1.6	38
39	Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis. Science Translational Medicine, 2021, 13, eabe6805.	12.4	36
40	Defined Conditions for the Isolation and Expansion of Basal Prostate Progenitor Cells of Mouse and Human Origin. Stem Cell Reports, 2015, 4, 503-518.	4.8	24
41	Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 160, 277-290.	2.5	23
42	One renegade cancer stem cell?. Cell Cycle, 2009, 8, 803-808.	2.6	22
43	Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Pancreas, 2017, 46, 311-322.	1.1	22
44	Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs. Molecular Cancer Research, 2021, 19, 688-701.	3.4	22
45	Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death and Differentiation, 2006, 13, 1740-1751.	11.2	19
46	Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1034-1046.	1.7	18
47	Label retaining cells in cancer â€“ The dormant root of evil?. Cancer Letters, 2013, 341, 73-79.	7.2	17
48	High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. Pancreatology, 2017, 17, 629-634.	1.1	16
49	Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Therapy, 2007, 14, 316-326.	4.6	15
50	Development and Characteristics of Preclinical Experimental Models for the Research of Rare Neuroendocrine Bladder Cancer. Journal of Urology, 2013, 190, 2263-2270.	0.4	14
51	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 173, 155-165.	2.5	11
52	Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. Clinical Cancer Research, 2007, 13, 6541-6542.	7.0	8
53	Protein profile of basal prostate epithelial progenitor cellsâ€”stageâ€specific embryonal antigen 4 expressing cells have enhanced regenerative potential in vivo. Journal of Cellular and Molecular Medicine, 2016, 20, 721-730.	3.6	5
54	The influence of prostatic anatomy and neurotrophins on basal prostate epithelial progenitor cells. Prostate, 2016, 76, 114-121.	2.3	2

#	Article	IF	Citations
55	Therapy resistance on the RADar in ovarian cancer. EMBO Molecular Medicine, 2021, 13, e14010.	6.9	2
56	Correction for Vermeulen et al., Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9534-9534.	7.1	0
57	Martin Leverkus, 1965â€“2016. Cell Death Discovery, 2017, 3, 16093.	4.7	0
58	Molekulare Basis fÃ¼r neue therapeutische AnsÃtze. , 2002, , 27-39.		0
59	Still a hopeless case for personalized oncology? Pancreatic cancer revisited. Oncoscience, 2018, 6, 285-286.	2.2	0